Tailored Digital Treatment for Migraine

Sponsor
Vastra Gotaland Region (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05617339
Collaborator
(none)
200
1
2
36
5.6

Study Details

Study Description

Brief Summary

Background: An individualized internet-based treatment program from a biopsychosocial perspective has been developed within the Västra Götaland region (VGR) with funds from the Innovation Fund. The treatment program is called Learn to live with migraine and goes by the abbreviation I AM (Internet Approach to Migraine). I AM is a complement to the medical treatment and focuses on pain management and learning to live as good a life as possible with the disease migraine. During the spring of 2022, I AM has been tested regarding the feasibility of primary care on 29 research subjects in a pilot RCT (DNR 2020-02359). A weighted preliminary assessment shows moderate effect size on mental health, that the participants accept the intervention, and that I AM with recruitment and care process can be carried out in a primary care context. Purpose: An overall purpose of the study is to evaluate the effect of the addition of the internet-based biopsychosocial treatment I AM compared to usual treatment (TREATMENT as usual - TAU) in primary care regarding frequency and severity of migraine attacks, functional level, mental health, quality of life and employment rate with a randomized controlled trial design (RCT). An additional aim is to evaluate whether it is possible to prevent episodic migraine from developing into chronic migraine among those who have episodic migraine at the start of the study via the supplement treatment program I AM. Expected results: The greatest expected benefit of I AM is to reduce the burden and suffering of migraines for all the people affected. AM is also expected to increase the availability of treatment with a biopsychosocial perspective, have a quality-enhancing effect in terms of method and increase the patient's participation in their treatment. An environmental aspect is that neither patient nor therapist need to travel, accessibility also increases for individuals living in smaller communities who receive equal treatment.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: I am (internet approach to migraine)
N/A

Detailed Description

An overall purpose of the study is to evaluate in a randomized controlled trial (RCT) the effect of the addition of the internet-based treatment Internet Approach to Migraine (I AM ) compared to usual treatment (Treatment as usual - TAU) in primary care regarding frequency and severity of migraine attacks, functional level, mental health, quality of life and employment rate. An additional aim is to evaluate whether it is possible to prevent episodic migraine, among those who have episodic migraine at the start of the study, from developing into chronic migraine in primary care via the addition of the I AM treatment program for migraine, compared to TAU.

Question / Hypothesis Impact evaluation - primary outcomes1. What effect does I AM have, in comparison with treatment as usual (TAU) regarding the frequency and severity of migraine as well as functional capacity, mental health and quality of life, in follow-up measurement after termination, at 6 months after the end of treatment, and at 1 year and 2 years of follow-up measurement? The hypothesis is that there is an interaction effect and that the participants in I AM at follow-ups have a significantly lower degree of frequency and severity of migraine, as well as better functional ability, mental health and quality of life.2. Is there a significant difference between how many people have developed chronic migraine (measured by cut off of 15 days a month?) in the I AM and TAU groups, respectively? The hypothesis being tested is that the frequency and severity of migraine attacks is not reduced or further developed by the targeted treatment program I AM in comparison with TAU.

Process Evaluation - Secondary outcomes3. What effect does I AM have in comparison to TAU regarding flexibility and acceptance, selfcompassion, mindfulness, degree of pain sensitivitization and confidence in one's ability to engage in physical training? How does the effect of the intervention stand after 6, 12 and 24 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Masking Description:
The groups are predetermined based on the tool randomizer.org and blinded to the researcher assigning the participants to groups.
Primary Purpose:
Treatment
Official Title:
Tailored Digital Treatment for Migraine
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Personalised internet-based treatment "I am".

Need-based internet-based treatment

Behavioral: I am (internet approach to migraine)
I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
Other Names:
  • Learn to live with migraine (Lär dig leva med migrän)
  • No Intervention: Treatment As Usual

    Control group, Treatment in primary care which is medical treatment

    Outcome Measures

    Primary Outcome Measures

    1. Headache Impact Test-6 (HIT-6) [Week 1]

      Frequency and severity of migraine attacks.Two questions are added in the present study: How many migraine days per month have you had on average in the last 3 months? Estimated on a scale of 1-10 how painful the headache was. 0= no pain and 10= worst imaginable pain. What percentage have you been employed in the last 3 months?

    2. Headache Impact Test-6 (HIT-6) [post (week 8 or 20)]

      Frequency and severity of migraine attacks.Two questions are added in the present study: How many migraine days per month have you had on average in the last 3 months? Estimated on a scale of 1-10 how painful the headache was. 0= no pain and 10= worst imaginable pain. What percentage have you been employed in the last 3 months?

    3. Headache Impact Test-6 (HIT-6) [6 months follow up]

      Frequency and severity of migraine attacks.Two questions are added in the present study: How many migraine days per month have you had on average in the last 3 months? Estimated on a scale of 1-10 how painful the headache was. 0= no pain and 10= worst imaginable pain. What percentage have you been employed in the last 3 months?

    4. Headache Impact Test-6 (HIT-6) [12 months follow up]

      Frequency and severity of migraine attacks.Two questions are added in the present study: How many migraine days per month have you had on average in the last 3 months? Estimated on a scale of 1-10 how painful the headache was. 0= no pain and 10= worst imaginable pain. What percentage have you been employed in the last 3 months?

    5. Headache Impact Test-6 (HIT-6) [24 months follow up]

      Frequency and severity of migraine attacks.Two questions are added in the present study: How many migraine days per month have you had on average in the last 3 months? Estimated on a scale of 1-10 how painful the headache was. 0= no pain and 10= worst imaginable pain. What percentage have you been employed in the last 3 months?

    Secondary Outcome Measures

    1. Mental Health Continuum Short Form (MHC-SF). [Week 1]

      Mental health and quality of life

    2. Mental Health Continuum Short Form (MHC-SF). [post (week 8 or 20)]

      Mental health and quality of life

    3. Mental Health Continuum Short Form (MHC-SF). [6 months follow up]

      Mental health and quality of life

    4. Mental Health Continuum Short Form (MHC-SF). [12 months follow up]

      Mental health and quality of life

    5. Mental Health Continuum Short Form (MHC-SF). [24 months follow up]

      Mental health and quality of life

    6. Swedish version of CORE-10 [Week 1]

      A broader measure of mental health in terms of well-being, symptoms, function and risk.

    7. Swedish version of CORE-10 [up to week 4 or 10.]

      A broader measure of mental health in terms of well-being, symptoms, function and risk.

    8. Swedish version of CORE-10 [post (week 8 or 20)]

      A broader measure of mental health in terms of well-being, symptoms, function and risk.

    9. Swedish version of CORE-10 [6 months follow up]

      A broader measure of mental health in terms of well-being, symptoms, function and risk.

    10. Swedish version of CORE-10 [12 months follow up]

      A broader measure of mental health in terms of well-being, symptoms, function and risk.

    11. Swedish version of CORE-10 [24 months follow up]

      A broader measure of mental health in terms of well-being, symptoms, function and risk.

    12. Self-Efficacy for Exercise Scale [Week 1]

      Their ability to conduct physical exercise

    13. Self-Efficacy for Exercise Scale [up to week 4 or 10.]

      Their ability to conduct physical exercise

    14. Self-Efficacy for Exercise Scale [post (week 8 or 20)]

      Their ability to conduct physical exercise

    15. Self-Efficacy for Exercise Scale [6 months follow up]

      Their ability to conduct physical exercise

    16. Self-Efficacy for Exercise Scale [12 months follow up]

      Their ability to conduct physical exercise

    17. Self-Efficacy for Exercise Scale [24 months follow up]

      Their ability to conduct physical exercise

    18. Five Facet Mindfulness Questionnaire [Week 1]

      Conscious

    19. Five Facet Mindfulness Questionnaire [post (week 8 or 20)]

      Conscious

    20. Five Facet Mindfulness Questionnaire [6 months follow up]

      Conscious

    21. Five Facet Mindfulness Questionnaire [12 months follow up]

      Conscious

    22. Five Facet Mindfulness Questionnaire [24 months follow up]

      Conscious

    23. Self-Compassion Scale [Week 1]

      Self compassion

    24. Self-Compassion Scale [post (week 8 or 20)]

      Self compassion

    25. Self-Compassion Scale [6 months follow up]

      Self compassion

    26. Self-Compassion Scale [12 months follow up]

      Self compassion

    27. Self-Compassion Scale [24 months follow up]

      Self compassion

    28. Two questions to Haskell 2007 - [Week 1]

      Physical activity Physical activity

    29. Two questions to Haskell 2007 - [up to week 20]

      Physical activity Physical activity

    30. Two questions to Haskell 2007 - [post (week 8 or 20)]

      Physical activity Physical activity

    31. Two questions to Haskell 2007 - [6 months follow up]

      Physical activity Physical activity

    32. Two questions to Haskell 2007 - [12 months follow up]

      Physical activity Physical activity

    33. Two questions to Haskell 2007 - [24 months follow up]

      Physical activity Physical activity

    34. Central Sensitization Inventory (CSI) [Week 1]

      Key symptoms associated with central sensitization

    35. Central Sensitization Inventory (CSI) [post (week 8 or 20)]

      Key symptoms associated with central sensitization

    36. Central Sensitization Inventory (CSI) [6 months follow up]

      Key symptoms associated with central sensitization

    37. Central Sensitization Inventory (CSI) [12 months follow up]

      Key symptoms associated with central sensitization

    38. Central Sensitization Inventory (CSI) [24 months follow up]

      Key symptoms associated with central sensitization

    39. Acceptance of the treatment [Post (week 8 or 20)]

      Acceptance of the treatment Measured with its own constructed form developed for the study. The form consists of four questions: Would you recommend the processing to someone else? How meaningful have you experienced the treatment scale 1-7, as well as two open questions answered in writing: what have you got out of the treatment? What has been less good about the treatment?

    40. Acceptance of the treatment [6 months follow up]

      Acceptance of the treatment Measured with its own constructed form developed for the study. The form consists of four questions: Would you recommend the processing to someone else? How meaningful have you experienced the treatment scale 1-7, as well as two open questions answered in writing: what have you got out of the treatment? What has been less good about the treatment?

    41. Acceptance of the treatment [12 months follow up]

      Acceptance of the treatment Measured with its own constructed form developed for the study. The form consists of four questions: Would you recommend the processing to someone else? How meaningful have you experienced the treatment scale 1-7, as well as two open questions answered in writing: what have you got out of the treatment? What has been less good about the treatment?

    42. Acceptance of the treatment [24 months follow up]

      Acceptance of the treatment Measured with its own constructed form developed for the study. The form consists of four questions: Would you recommend the processing to someone else? How meaningful have you experienced the treatment scale 1-7, as well as two open questions answered in writing: what have you got out of the treatment? What has been less good about the treatment?

    43. Other treatment [post (week 8 or 20)]

      "Other treatment" is measured with the question: Have you since you finished the treatment I AM, Learn to live with migraine or since the last self-assessment received other treatment for migraine? If yes, please describe which one.

    44. Other treatment [6 months follow up]

      "Other treatment" is measured with the question: Have you since you finished the treatment I AM, Learn to live with migraine or since the last self-assessment received other treatment for migraine? If yes, please describe which one.

    45. Other treatment [12 months follow up]

      "Other treatment" is measured with the question: Have you since you finished the treatment I AM, Learn to live with migraine or since the last self-assessment received other treatment for migraine? If yes, please describe which one.

    46. Other treatment [24 months follow up]

      "Other treatment" is measured with the question: Have you since you finished the treatment I AM, Learn to live with migraine or since the last self-assessment received other treatment for migraine? If yes, please describe which one.

    47. Bulls eye [Week 1]

      Behavioral activation in a valued direction was measured with a Swedish version of Bulls eye (Lundgren, Louma, Dahl, Strohsal &melin, 2012). The self-assessment scale is divided into four areas of values in people's lives: work/education, leisure, relationships and self-care/health. The instrument has demonstrated a test-retest reliability of 0.86 and good kriterieva deaths (Lundgren, Dahl &hayes, 2008).

    48. Bulls eye [up to week 20]

      Behavioral activation in a valued direction was measured with a Swedish version of Bulls eye (Lundgren, Louma, Dahl, Strohsal &melin, 2012). The self-assessment scale is divided into four areas of values in people's lives: work/education, leisure, relationships and self-care/health. The instrument has demonstrated a test-retest reliability of 0.86 and good kriterieva deaths (Lundgren, Dahl &hayes, 2008).

    49. Bulls eye [post (week 8 or 20)]

      Behavioral activation in a valued direction was measured with a Swedish version of Bulls eye (Lundgren, Louma, Dahl, Strohsal &melin, 2012). The self-assessment scale is divided into four areas of values in people's lives: work/education, leisure, relationships and self-care/health. The instrument has demonstrated a test-retest reliability of 0.86 and good kriterieva deaths (Lundgren, Dahl &hayes, 2008).

    50. Bulls eye [6 months follow up]

      Behavioral activation in a valued direction was measured with a Swedish version of Bulls eye (Lundgren, Louma, Dahl, Strohsal &melin, 2012). The self-assessment scale is divided into four areas of values in people's lives: work/education, leisure, relationships and self-care/health. The instrument has demonstrated a test-retest reliability of 0.86 and good kriterieva deaths (Lundgren, Dahl &hayes, 2008).

    51. Bulls eye [12 months follow up]

      Behavioral activation in a valued direction was measured with a Swedish version of Bulls eye (Lundgren, Louma, Dahl, Strohsal &melin, 2012). The self-assessment scale is divided into four areas of values in people's lives: work/education, leisure, relationships and self-care/health. The instrument has demonstrated a test-retest reliability of 0.86 and good kriterieva deaths (Lundgren, Dahl &hayes, 2008).

    52. Bulls eye [24 months follow up]

      Behavioral activation in a valued direction was measured with a Swedish version of Bulls eye (Lundgren, Louma, Dahl, Strohsal &melin, 2012). The self-assessment scale is divided into four areas of values in people's lives: work/education, leisure, relationships and self-care/health. The instrument has demonstrated a test-retest reliability of 0.86 and good kriterieva deaths (Lundgren, Dahl &hayes, 2008).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women and men

    • 18 years and up

    • diagnosed episodic or chronic migraine with or without aura 3 or more migraine days a month.

    • Access to computer / tablet or smartphone with Bankid and internet connection.

    Exclusion Criteria:
    • ongoing malignant disease

    • other rarer migraine diseases such as cluster headache, basilar migraine, hemiplegis migraine, vestibular migraine and eye migraine

    • ongoing moderate to more severe psychiatric problems such as depression, anxiety disorders, neuropsychiatric conditions, psychotic disorders, substance abuse and personality disorders

    • Ongoing psychological/physiotherapeutic treatment

    • People who cannot read, speak or understand the Swedish language

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 FoU primary care Södra Älvsborg Borås Sven Eriksonsplatsen 4 Sweden 503 38

    Sponsors and Collaborators

    • Vastra Gotaland Region

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Vastra Gotaland Region
    ClinicalTrials.gov Identifier:
    NCT05617339
    Other Study ID Numbers:
    • VGFOUREG-979683
    First Posted:
    Nov 15, 2022
    Last Update Posted:
    Nov 15, 2022
    Last Verified:
    Oct 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Vastra Gotaland Region
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 15, 2022